Skip to main content
Clinical Trials/NCT03795064
NCT03795064CompletedNot Applicable

Immediate Versus Early Endovenous Ablation In Venous Ulcer

Oulu University Hospital2 sites in 1 country23 target enrollmentStarted: December 5, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
23
Locations
2
Primary Endpoint
Venous ulcer area

Study Overview

Brief Summary

The study is conducted to assess the effects of immediately started foam sclerotherapy in venous ulcer compared to early intervention.

Detailed Description

Recently EVRA study showed that early endovenous ablation (foam sclerotherapy and/or endothermal ablation) is beneficial for venous ulcer healing. This randomized controlled trial is conducted to assess the effects of immediate foam sclerotherapy in the first visit to vascular outpatient clinic (immediate intervention). Patients in control group will receive foam sclerotherapy at four weeks (early intervention). Endothermal ablation is performed in early setting in both groups when truncal vein anatomy is suitable. The primary outcome for this study is the reduction of venous ulcer area at four weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Venous ulcer > 1 month
  • Ulcer area > 1cm2
  • Palpable distal pulses / Ankle-brachial index > 0,8 / Toe-brachial index > 70mmhg (at least one criteria must be met)

Exclusion Criteria

  • Leg ulcers other than venous etiology
  • Pregnancy
  • General contraindications for foam sclerotherapy
  • Ulcers requiring operation theater revision

Outcomes

Primary Outcomes

Venous ulcer area

Time Frame: 0 to 180 days

Venous ulcer area measured from calibrated digital photograph.

Secondary Outcomes

  • Time to ulcer healing(0 to 360 days)
  • Total time of active venous ulcer(0 to 360 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Toni Pihlaja

Vascular Specialist

Oulu University Hospital

Study Sites (2)

Loading locations...

Similar Trials